More kids in the United States are getting a developmental disability diagnosis, with prevalence close to 9% in 2021, the U.S. Centers for Disease Control and Prevention reports. Among 3- to 17-year-olds, 8.56% have ever been diagnosed with a developmental disability, compared to 7.4% in 2019, according to the agency’s National Health Interview Survey. The…  read on >  read on >

Older adults who regularly spend time with family and friends may have bigger brains to show for it, a new study suggests. Healthy brain aging is a complex matter, and researchers are still trying to understand which factors keep the mind sharp and which ones feed declines in memory and thinking. But a number of…  read on >  read on >

The U.S. Food and Drug Administration on Thursday approved the nation’s first over-the-counter birth control pill, a move that will likely pave the way for far greater access to contraception for Americans. Women will be able to buy the progestin-only oral contraceptive at drug stores, convenience stores and grocery stores, the FDA said. There is…  read on >  read on >

About one-fifth of American workers say their workplace is toxic, and many say their mental health is harmed as a result. The American Psychological Association (APA) questioned 2,515 employed adults in April for its annual Work in America Survey. Nineteen percent stated that their workplace is very or somewhat toxic. “The number of individuals who…  read on >  read on >

A bunch of healthy fruits and vegetables could be just what the doctor ordered. Nonprofit groups and public health agencies have experimented with the idea of a produce prescription over the years. Now, a new study simulates what would happen if patients with diabetes and diet-related conditions were given free or discounted produce and nutrition…  read on >  read on >

A targeted treatment has had unprecedented success in shrinking a rare brain tumor, according to clinical trial results. These tumors are papillary craniopharyngiomas (PCPs), and the drug combo is called vemurafenib/cobimetinib. Each of 15 patients who received one or more cycles of targeted therapy responded to treatment, with an average 91% reduction in tumor size,…  read on >  read on >